Envoy Medical announced that all 56 patients in its pivotal clinical trial for the fully implanted Acclaim cochlear implant have reached the three-month milestone. This progress is a key step toward the company's goal of submitting a Premarket Approval (PMA) application to the FDA. The trial continues to collect safety and efficacy data, with six-month and 12-month milestones expected by late 2026 and April 2027, respectively. The Acclaim implant represents a novel hearing solution designed for severe to profound sensorineural hearing loss, leveraging natural ear anatomy for sound capture without external components.
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
United Rentals is set to report its Q2 2026 earnings on July 22, with analysts forecasting an 11.5% rise in earnings per share to $11.67 and a 7.3% increase in revenue to $4.23 billion. The growth is driven by strong rental demand and efficient equip...
Analyst firm BTIG initiated a Buy rating on Philip Morris International, with the stock trading at $188.04. They project strong Q2 earnings of $2.05 per share and revenue growth to $10.64 billion, up from last year. The company also offers an attract...
